What the business is, and whether it's a good one at a fair price.
Operates as a global Contract Research, Development and Manufacturing Organization (CRDMO), providing outsourced research, development and manufacturing services to pharmaceutical and biotechnology companies. Works with around 400 global customers and runs a workforce of over 8,300 employees. The business spans small-molecule CDMO work and a large-molecule / biologics CDMO (LMCDMO) franchise, supported by a material subsidiary, Syngene Scientific Solutions Limited, and the recently strengthened Syn.AI platform. FY26 revenue stood at Rs 3,738.7 crore with an EBITDA margin of 24.4%, but Q1 FY27 revenue fell 16% year-on-year to Rs 736 crore and EBITDA margin compressed to 12%, driven by lower offtake from a major biologics client and forex hedge losses. Employee costs are the largest expense at 29.6% of revenue, followed by materials at 24.4%, other operating expenses at 21.3% and depreciation at 12.1%, with capex running at 9.2% of revenue.
Measured from the filed financials, judged against its Healthcare Services peers · as of FY26 — not investment advice
How has the market priced it — with filings on the timeline?
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
How does it stack up on valuation, returns and growth?
Loading peers…
Quarterly & annual P&L, balance sheet, cash flow, ratios and segments.
Loading financials…
Who owns it — and is the promoter stake clean?
Loading shareholding…
Sign up to see the full company file
Governance, sustainability, compliance, earnings calls, presentations, events, reactions and the full filings feed — free with an account.
Answered from SYNGENE INTERNATIONAL LTD's filed financials and exchange disclosures
SYNGENE INTERNATIONAL LTD is a Healthcare Services company listed on NSE and BSE, trading under the symbol SYNGENE.
Yes. Over the trailing twelve months SYNGENE INTERNATIONAL LTD reported a net profit of ₹221 Cr on revenue of ₹3,600 Cr.
Yes. The dividend yield is 0.33% at the current price. It paid out 16% of its profit as dividend in FY26.
Effectively yes. It holds ₹219 Cr more cash than debt. Debt stands at 0.00× equity.
On trailing P/E, SYNGENE INTERNATIONAL LTD ranks 58 of 68 in Healthcare Services — cheaper than 15% of them, against an industry median of 31.2×. This is a position, not a valuation judgement.
On a typical session SYNGENE INTERNATIONAL LTD moves 1.14% — that is the median absolute close-to-close move across its last 269 trading days. Announcement days are routinely larger.
Every NSE and BSE filing by SYNGENE INTERNATIONAL LTD appears on this page, AI-summarised, alongside the price reaction that followed it. Follow the company to get each new filing on WhatsApp within minutes.
Figures are as last reported and may lag the latest filing. Not investment advice.
